BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN
BEGIN:VEVENT
DESCRIPTION:Taking decisions during the development of a new drug requires
combining many and varying pieces of information. The interconnections bet
ween them are often only partially known\, reflecting the complexity of th
e context in which drugs are evaluated and the cognitive load required for
health care decisions. Decision-makers need quantitative tools to support
informed decisions\, with transparent processes that synthesize the whole
available information in order to evaluate the success associated to diff
erent options.\n\nThis meeting aims to bring together statisticians from t
he pharmaceutical industry and academia to hear about recent advances in s
tatistical methods for quantitative decision-making in drug development.\n
\nConfirmed speakers include:\n\n\n \n \n Anthony O'H
agan\n University of Sheffield \;\n Introduction
to decision-making\n \n \n Juan Abellan\n
GSK\n Prior elicitation to support quantitative decision-m
aking\n \n \n Paul Frewer\n Astra Zene
ca\n Decision Making in Early Clinical Development: The framewo
rk used within AstraZeneca\n \n \n Maria Costa\n
Novartis\n Benefit-Risk Assessment in Drug Developme
nt\n \n \n \n Nigel Stallard\n
University of Warwick\n Decision-making in phase II/III tri
als using early endpoint data\n \n \n \n
Tom Parke\n Berry Consultants\n \n Usi
ng simulations to optimize drug development decision-making\n \
n \n \n\n\nPoster Session - Call for Abstracts:\n\nIf you wish t
o present a poster\, please send an abstract to Gaë\;lle Saint-Hilary
(gsainthilary@gmail.com) by October 31st 2018. The notification of accepta
nce will be provided by November 9th 2018.\n\nFor more details and to view
the flyer\, please click here.
DTEND;VALUE=DATE:20181213
DTSTAMP:20240329T152957Z
DTSTART;VALUE=DATE:20181212
LOCATION:
SEQUENCE:0
SUMMARY:Decision-making in drug development
UID:RFCALITEM638473229978435189
X-ALT-DESC;FMTTYPE=text/html:Taking decisions during the development of a n
ew drug requires combining many and varying pieces of information. The int
erconnections between them are often only partially known\, reflecting the
complexity of the context in which drugs are evaluated and the cognitive
load required for health care decisions. Decision-makers need quantitative
tools to support informed decisions\, with transparent processes that syn
thesize the whole available information in order to evaluate the success a
ssociated to different options.
\n
\nThis meeting aims to bring
together statisticians from the pharmaceutical industry and academia to he
ar about recent advances in statistical methods for quantitative decision-
making in drug development.
\n
\nConfirmed speakers incl
ude:
\n
\n
Anthony O
'Hagan \n University of Sheffield \; | \n
Introduction to decisio n-making | \n
Juan
Abellan \n GSK | \n Prior elicitation to support quantitative decisio n-making | \n
Paul
Frewer \n Astra Zeneca | \n Decision Making in Early Clinical Develo pment: The framework used within AstraZeneca | \n
Maria Costa \n Nov artis | \n Benefit-R
isk Assessment in Drug Development \n | \n
Nigel Stallard \n University of Warwick | \n Decision-making in phase II/III trials using early endpo
int data \n | \n
Tom Parke \n Berry Consultants \n | \n Using simulations to optimize drug development decision-making \n | \n